Is Alzheimer's disease amyloidosis the result of a repair mechanism gone astray?-Reference-Cited by-同舟云学术

Is Alzheimer's disease amyloidosis the result of a repair mechanism gone astray?

Published:2011-11-03 Issue:6 Volume:8 Page:574-583
ISSN:1552-5260
Container-title:Alzheimer's & Dementia
language:en
Short-container-title:Alzheimer's & Dementia

Author:

Kokjohn Tyler A.¹²,Maarouf Chera L.¹,Roher Alex E.¹

Affiliation:

1. The Longtine Center for Neurodegenerative Biochemistry Banner Sun Health Research InstituteSun CityAZUSA

2. Department of MicrobiologyMidwestern UniversityGlendaleAZUSA

Funder

National Institute on Aging

Publisher

Wiley

Subject

Psychiatry and Mental health,Cellular and Molecular Neuroscience,Geriatrics and Gerontology,Neurology (clinical),Developmental Neuroscience,Health Policy,Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1016/j.jalz.2011.05.2429

Reference129 articles.

1. The biochemical aftermath of anti-amyloid immunotherapy

2. Neuropathology and Amyloid-β Spectrum in a Bapineuzumab Immunotherapy Recipient

3. Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial

4. WongGT.FDA deems U. S. Alzhemed trial results inconclusive.Alzheimer Research Forum. Available at:http://www.alzforum.org/new/detail.asp?id=1647 ; August 28 2007.

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Review of valiltramiprosate (ALZ-801) for the treatment of Alzheimer’s disease: a novel small molecule with disease modifying potential;Expert Opinion on Pharmacotherapy;2024-05-02

2. Role of monomeric amyloid-β in cognitive performance in Alzheimer's disease: Insights from clinical trials with secretase inhibitors and monoclonal antibodies;Pharmacological Research;2023-01

3. HSF-1 mediated combined ginsenosides ameliorating Alzheimer’s disease like symptoms in Caernorhabditis elegans;Nutritional Neuroscience;2021-07-15

4. Overexpression of HIF-2α in Protected Regions of Alzheimer’s disease Resilient Cases;2020-09-01

5. Anti-amyloid-β protein agents for the treatment of Alzheimer’s disease: an update on emerging drugs;Expert Opinion on Emerging Drugs;2020-07-02